BridgeBio Pharma Inc Dossier
Qualitative Analysis
Business overview
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a commercial-stage biopharmaceutical company founded in 2015 to discover, create, test, and deliver transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers. The company utilizes a decentralized, program-specific corporate structure designed to advance multiple therapeutic candidates simultaneously. Its lead commercial product is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). BridgeBio's extensive pipeline spans early-stage research to advanced clinical trials, targeting Mendelian disorders, precision oncology, and gene therapies.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Building out commercial infrastructure in the United States and Europe to accelerate the market uptake of Attruby (acoramidis) for ATTR-CM.
Expected impact: Aims to capture significant market share in the multi-billion dollar ATTR-CM market and drive the company toward cash flow positivity.
Deconsolidating non-core subsidiaries and assets, such as Portal Therapeutics and Sub21 into GondolaBio, and BridgeBio Oncology Therapeutics (BBOT) following private financing, to focus resources on core late-stage programs.
Expected impact: Reduces operational cash burn and sharpens corporate focus on high-value late-stage clinical assets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Bayer holds exclusive rights to develop and commercialize acoramidis (as Beyonttra) in the European Union and associated territories, leveraging Bayer's established commercial network.
Terms: Included a $135.0 million upfront payment, a $75.0 million milestone payment upon European Commission approval in 2025, and potential milestone payments up to $175.0 million through 2026 plus sales royalties.
Collaborating to develop and commercialize infigratinib for skeletal dysplasias in Japan.
Terms: Included an upfront payment of $100.0 million and potential royalties up to the mid-twenties percent on sales.
Monetizing future European royalty streams to secure non-dilutive capital for pipeline advancement.
Terms: BridgeBio sold certain royalty rights on European net sales of acoramidis for $300.0 million in cash, subject to an annual cap of 60% on the first $500.0 million of annual net sales and an initial hard cap of 145% of the purchase price.